GANX: Gain Therapeutics Inc Financial Statements
Balance sheet, income statement, and cash flow statements for Gain Therapeutics Inc (GANX).
$57.29M Market Cap.
GANX Market Cap. (MRY)
GANX Shares Outstanding (MRY)
GANX Assets (MRY)
Total Assets
$12.12M
Total Liabilities
$4.78M
Total Investments
$31.70K
GANX Income (MRY)
Revenue
$0
Net Income
-$20.41M
Operating Expense
$20.35M
GANX Cash Flow (MRY)
CF Operations
-$18.87M
CF Investing
$4.98M
CF Financing
$13.01M
GANX Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Total Assets | $12,123,884 (-34.85%) | $18,609,331 (-22.78%) | $24,099,387 (-38.18%) | $38,985,071 (305.91%) |
Assets Current | $11,602,478 (-34.74%) | $17,778,868 (-15.71%) | $21,091,296 (-44.09%) | $37,722,044 (319.70%) |
Assets Non-Current | $521,406 (-37.22%) | $830,463 (-72.39%) | $3,008,091 (138.17%) | $1,263,027 (104.86%) |
Goodwill & Intangible Assets | $134,268 (-30.57%) | $193,375 (-9.62%) | $213,967 (5.61%) | $202,609 (0%) |
Shareholders Equity | $7,339,574 (-41.65%) | $12,578,224 (-33.38%) | $18,879,514 (-45.78%) | $34,817,546 (461.39%) |
Property Plant & Equipment Net | $323,334 (-44.75%) | $585,177 (-27.25%) | $804,312 (-20.13%) | $1,007,028 (82.20%) |
Cash & Equivalents | $10,385,863 (-11.95%) | $11,794,949 (61.32%) | $7,311,611 (-80.17%) | $36,880,673 (391.46%) |
Accumulated Other Comprehensive Income | -$247,549 (-200.12%) | $247,241 (593.97%) | $35,627 (139.30%) | -$90,645 (40.64%) |
Deferred Revenue | $299,652 (-75.38%) | $1,216,924 (2105.37%) | $55,180 (-79.29%) | $266,504 (11.28%) |
Total Investments | $31,695 (-99.37%) | $5,033,725 (-65.99%) | $14,799,260 (47213.72%) | $31,279 (0%) |
Investments Current | $0 (0%) | $4,999,704 (-61.02%) | $12,826,954 (0%) | $0 (0%) |
Investments Non-Current | $31,695 (-6.84%) | $34,021 (-98.28%) | $1,972,306 (6205.53%) | $31,279 (0%) |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Receivables | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Payables | $946,259 (-28.26%) | $1,318,965 (-18.89%) | $1,626,100 (190.13%) | $560,479 (-41.71%) |
Accumulated Retained Earnings (Deficit) | -$81,194,908 (-33.58%) | -$60,783,717 (-57.81%) | -$38,516,197 (-84.06%) | -$20,925,459 (-197.45%) |
Tax Assets | $271,079 (11.75%) | $242,577 (133.52%) | $103,877 (-8.55%) | $113,586 (95.78%) |
Tax Liabilities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Debt | $653,015 (-36.44%) | $1,027,398 (-19.37%) | $1,274,257 (-20.78%) | $1,608,484 (27.52%) |
Debt Current | $271,090 (-22.21%) | $348,490 (3.34%) | $337,215 (4.41%) | $322,963 (122.15%) |
Debt Non-Current | $381,925 (-43.74%) | $678,908 (-27.55%) | $937,042 (-27.11%) | $1,285,521 (15.19%) |
Total Liabilities | $4,784,310 (-20.67%) | $6,031,107 (15.54%) | $5,219,873 (25.25%) | $4,167,525 (22.49%) |
Liabilities Current | $3,911,321 (-20.98%) | $4,949,959 (19.99%) | $4,125,251 (61.61%) | $2,552,546 (20.70%) |
Liabilities Non-Current | $872,989 (-19.25%) | $1,081,148 (-1.23%) | $1,094,622 (-32.22%) | $1,614,979 (25.43%) |
GANX Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Revenues | $0 (0%) | $55,180 (-60.62%) | $140,108 (-15.08%) | $164,994 (471.29%) |
Cost of Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Selling General & Administrative Expense | $9,559,534 (-11.38%) | $10,787,700 (13.08%) | $9,539,863 (39.74%) | $6,826,938 (446.54%) |
Research & Development Expense | $10,791,058 (-6.33%) | $11,520,613 (37.52%) | $8,377,290 (16.93%) | $7,164,229 (217.11%) |
Operating Expenses | $20,350,592 (-8.78%) | $22,308,313 (24.51%) | $17,917,153 (28.06%) | $13,991,167 (298.80%) |
Interest Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Income Tax Expense | $536,815 (577.16%) | $79,275 (-14.74%) | $92,976 (2219.76%) | $4,008 (-25.58%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$20,411,191 (8.34%) | -$22,267,520 (-26.59%) | -$17,590,738 (-26.64%) | -$13,890,606 (-288.26%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$20,411,191 (8.34%) | -$22,267,520 (-26.59%) | -$17,590,738 (-26.64%) | -$13,890,606 (-288.26%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$20,411,191 (8.34%) | -$22,267,520 (-26.59%) | -$17,590,738 (-26.64%) | -$13,890,606 (-288.26%) |
Weighted Average Shares | $22,881,415 (75.86%) | $13,011,361 (9.49%) | $11,883,368 (16.90%) | $10,165,404 (279.11%) |
Weighted Average Shares Diluted | $22,881,415 (75.86%) | $13,011,361 (9.49%) | $11,883,368 (16.90%) | $10,165,404 (279.11%) |
Earning Before Interest & Taxes (EBIT) | -$19,874,376 (10.43%) | -$22,188,245 (-26.81%) | -$17,497,762 (-26.00%) | -$13,886,598 (-288.73%) |
Gross Profit | $0 (0%) | $55,180 (-60.62%) | $140,108 (-15.08%) | $164,994 (471.29%) |
Operating Income | -$20,350,592 (8.55%) | -$22,253,133 (-25.18%) | -$17,777,045 (-28.58%) | -$13,826,173 (-297.37%) |
GANX Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Net Cash Flow from Investing | $4,977,507 (-51.31%) | $10,222,667 (169.19%) | -$14,774,813 (-15582.52%) | -$94,212 (-352.38%) |
Net Cash Flow from Financing | $13,012,076 (2.93%) | $12,641,343 (16147.61%) | -$78,774 (-100.19%) | $41,766,775 (298.27%) |
Net Cash Flow from Operations | -$18,873,827 (-0.04%) | -$18,865,873 (-28.41%) | -$14,692,139 (-18.81%) | -$12,365,670 (-281.63%) |
Net Cash Flow / Change in Cash & Cash Equivalents | -$1,411,412 (-131.46%) | $4,486,541 (115.17%) | -$29,569,523 (-200.55%) | $29,407,671 (308.97%) |
Net Cash Flow - Business Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | $5,000,000 (-51.16%) | $10,238,025 (169.86%) | -$14,655,860 (0%) | $0 (0%) |
Capital Expenditure | -$22,493 (-46.46%) | -$15,358 (87.09%) | -$118,953 (-26.26%) | -$94,212 (-352.38%) |
Issuance (Repayment) of Debt Securities | -$90,879 (-2.03%) | -$89,067 (-13.07%) | -$78,774 (-258.86%) | -$21,951 (-102.97%) |
Issuance (Purchase) of Equity Shares | $13,383,822 (5.13%) | $12,730,410 (0%) | $0 (0%) | $42,642,214 (24091546.33%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | -$527,168 (-207.94%) | $488,404 (2152.38%) | -$23,797 (-123.61%) | $100,778 (385.35%) |
Share Based Compensation | $2,390,159 (-26.66%) | $3,259,026 (113.51%) | $1,526,434 (81.85%) | $839,371 (928.14%) |
Depreciation Amortization & Accretion | $84,071 (0.59%) | $83,579 (30.25%) | $64,168 (314.41%) | $15,484 (61.43%) |
GANX Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Gross Margin | - | 100.00% (0.00%) | 100.00% (0.00%) | 100.00% (0.00%) |
Profit Margin | - | -40354.30% (-221.42%) | -12555.10% (-49.13%) | -8418.90% (32.04%) |
EBITDA Margin | - | -40059.20% (-221.94%) | -12443.00% (-48.01%) | -8407.00% (31.85%) |
Return on Average Equity (ROAE) | -222.60% (-15.34%) | -193.00% (-175.32%) | -70.10% (-99.72%) | -35.10% (71.78%) |
Return on Average Assets (ROAA) | -135.50% (-9.98%) | -123.20% (-113.52%) | -57.70% (-81.45%) | -31.80% (54.38%) |
Return on Sales (ROS) | - | -40210.70% (-221.97%) | -12488.80% (-48.39%) | -8416.40% (31.96%) |
Return on Invested Capital (ROIC) | 1091.80% (420.83%) | -340.30% (-111.89%) | -160.60% (94.38%) | -2858.90% (-272.59%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% |
Price to Earnings Ratio (P/E) | -2.43 (-27.13%) | -1.91 (9.74%) | -2.12 (46.64%) | -3.96 |
Price to Sales Ratio (P/S) | - | 769.88 (190.00%) | 265.47 (-20.65%) | 334.55 |
Price to Book Ratio (P/B) | 7.81 (132.95%) | 3.35 (70.10%) | 1.97 (6.31%) | 1.85 |
Debt to Equity Ratio (D/E) | 0.65 (36.12%) | 0.48 (73.55%) | 0.28 (130.00%) | 0.12 (-78.14%) |
Earnings Per Share (EPS) | -0.89 (47.95%) | -1.71 (-15.54%) | -1.48 (-8.03%) | -1.37 (-3.01%) |
Sales Per Share (SPS) | 0 (0%) | 0 (-66.67%) | 0.01 (-25.00%) | 0.02 (45.45%) |
Free Cash Flow Per Share (FCFPS) | -0.83 (43.07%) | -1.45 (-16.45%) | -1.25 (-1.63%) | -1.23 (-0.82%) |
Book Value Per Share (BVPS) | 0.32 (-66.80%) | 0.97 (-39.14%) | 1.59 (-53.61%) | 3.42 (48.08%) |
Tangible Assets Book Value Per Share (TABVPS) | 0.52 (-62.97%) | 1.42 (-29.60%) | 2.01 (-47.31%) | 3.81 (6.50%) |
Enterprise Value Over EBIT (EV/EBIT) | -2 (0.00%) | -2 (0.00%) | -2 (0.00%) | -2 |
Enterprise Value Over EBITDA (EV/EBITDA) | -2.33 (-32.03%) | -1.76 (-11.31%) | -1.58 (12.16%) | -1.8 |
Asset Turnover | 0 (0%) | 0 (-40.00%) | 0.01 (25.00%) | 0 (-33.33%) |
Current Ratio | 2.97 (-17.43%) | 3.59 (-29.75%) | 5.11 (-65.40%) | 14.78 (247.72%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$18,896,320 (-0.08%) | -$18,881,231 (-27.48%) | -$14,811,092 (-18.87%) | -$12,459,882 (-282.08%) |
Enterprise Value (EV) | $46,014,038 (18.23%) | $38,918,609 (41.09%) | $27,584,072 (10.42%) | $24,981,318 |
Earnings Before Tax (EBT) | -$19,874,376 (10.43%) | -$22,188,245 (-26.81%) | -$17,497,762 (-26.00%) | -$13,886,598 (-288.73%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$19,790,305 (10.47%) | -$22,104,666 (-26.79%) | -$17,433,594 (-25.68%) | -$13,871,114 (-289.34%) |
Invested Capital | -$1,654,553 (-161.32%) | $2,698,446 (-80.34%) | $13,722,815 (1332.85%) | $957,727 (-23.17%) |
Working Capital | $7,691,157 (-40.05%) | $12,828,909 (-24.38%) | $16,966,045 (-51.76%) | $35,169,498 (411.71%) |
Tangible Asset Value | $11,989,616 (-34.90%) | $18,415,956 (-22.90%) | $23,885,420 (-38.41%) | $38,782,462 (303.80%) |
Market Capitalization | $57,294,147 (35.92%) | $42,152,267 (13.33%) | $37,194,942 (-42.34%) | $64,507,004 |
Average Equity | $9,168,939 (-20.51%) | $11,535,164 (-54.04%) | $25,096,680 (-36.55%) | $39,553,924 (1275.28%) |
Average Assets | $15,065,730 (-16.64%) | $18,072,557 (-40.70%) | $30,478,396 (-30.31%) | $43,735,406 (752.16%) |
Invested Capital Average | -$1,820,352 (-127.92%) | $6,519,592 (-40.14%) | $10,892,039 (2142.40%) | $485,732 (4.34%) |
Shares | 26,525,068 (105.46%) | 12,910,342 (8.64%) | 11,883,368 (0.03%) | 11,879,743 (4.84%) |